Five-Year pill aimed at stopping lung Cancer's return
NCT ID NCT05526755
Summary
This study is testing whether taking a daily pill called osimertinib for five years can prevent lung cancer from returning in people who have had surgery to remove their tumor. It is for adults with a specific genetic type of non-small cell lung cancer (stages II-IIIB). The main goal is to see if this long-term treatment safely increases the time people live without their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II-IIIB NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Santa Rosa, California, 95403, United States
-
Research Site
Las Vegas, Nevada, 89169, United States
-
Research Site
White Plains, New York, 10601, United States
-
Research Site
Hong Kong, 150001, Hong Kong
-
Research Site
Hong Kong, 999077, Hong Kong
-
Research Site
Hong Kong, Hong Kong
-
Research Site
Avellino, 83100, Italy
-
Research Site
Brescia, 25123, Italy
-
Research Site
Lecce, 73100, Italy
-
Research Site
Milan, 20141, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Palermo, 90146, Italy
-
Research Site
Peschiera del Garda, 37019, Italy
-
Research Site
Reggio Emilia, 42123, Italy
-
Research Site
Sondrio, 23100, Italy
-
Research Site
Terni, 05100, Italy
-
Research Site
Udine, 33100, Italy
-
Research Site
Kuala Lumpur, 59100, Malaysia
-
Research Site
Kuantan, 25100, Malaysia
-
Research Site
Kuching, 93586, Malaysia
-
Research Site
Cebu, 6000, Philippines
-
Research Site
Manila, 1000, Philippines
-
Research Site
Quezon City, 1100, Philippines
-
Research Site
Singapore, 119074, Singapore
-
Research Site
Busan, 48108, South Korea
-
Research Site
Busan, 49241, South Korea
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Daejeon, 35015, South Korea
-
Research Site
Goyang-si, 410-769, South Korea
-
Research Site
Gyeonggi-do, 13620, South Korea
-
Research Site
Incheon, 21565, South Korea
-
Research Site
Seongnam-si, 13496, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05030, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Badalona, 08013, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Bilbao, 48013, Spain
-
Research Site
Granada, 18014, Spain
-
Research Site
L'Hospitalet de Llobregat, 08907, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Seville, 41009, Spain
-
Research Site
Valencia, 46026, Spain
-
Research Site
Hualien City, 970, Taiwan
-
Research Site
Kaohsiung City, 82445, Taiwan
-
Research Site
Kaohsiung City, 833401, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Taipei, 10449, Taiwan
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Songkhla, 90110, Thailand
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
Conditions
Explore the condition pages connected to this study.